Hewitt et al. designed a weakly supervised DL pipeline to predict glioma subtype by utilizing both 2016 and 2021 WHO classification schemes and predicting the core molecular alterations—IDH mutation, 1p19q codeletion, and ATRX mutation (AUC 0.90, 0.79, & 0.87) [16]. The gene discussed is IDH2; the disease is glioma.